Speakers

David Blair

David Blair

David studied chemistry at Oxford and holds an MBA from Manchester Business School. After qualifying with Price Waterhouse in 1987 he spent four years in the firm’s corporate finance department, leaving to lead a successful MBI team.

He has specialised in advising SMEs in the life science and technology arenas and in the last 20 years has assisted around 50 companies to raise and deploy in excess of ?200m from public and private funds as well as steering them through a variety of corporate transactions. He has also worked closely with providers of finance to the sector, for 4 years as Company Secretary of Prelude Trust plc, a main market listed Investment Trust. Since 2008 he has been CFO of Wyvern Fund, which invests in early stage technology companies.

A member of the Corporate Finance and Finance and Management Faculties of the Institute of Chartered Accountants; he is also a current member of the Institute Council and Past President of the East Anglia District Society.


Tony Bradshow

Tony Bradshow

PhD from Heriot Watt University, Edinburgh and more recently a coaching qualification from Henley Business School.

Experience working across the public, private and academic sectors in the Biotechnology field for organisations such as British Sugar, University College London, BioIndustry Association and Knowledge Transfer Network. This has involved science, business development, operational and Talent Management roles. In addition, 5 years as an executive search consultant recruiting staff for European Biotechnology companies.

Recently established Bradshaw Talent Management focussing on career coaching, corporate talent management programmes and connecting academia with industry. Further details in LinkedIn at http://linkedin.com/in/drtonybradshaw


Anne Bruinvels

Anne Bruinvels

Anne Bruinvels is a serial life-sciences entrepreneur and recently was appointed as a NHS Innovation Accelerator Fellow. She founded Px HealthCare (Px stands for Patient Experience), which has launched OWise, the validated mobile app platform providing cancer patients with personalised medical support tools. It collects and analyses the anonymised, real-time Patient Reported Outcome data to improve clinical outcomes in cancer.

Prior to setting up Px, Anne founded Curidium, a genomics data-mining company focused on identifying diagnostics and therapeutics to treat patients with central nervous system disorders more effectively. With Curidium's she raised several rounds of angel funding before taking the company public on the AIM of the London Stock Exchange. Prior to founding Curidium, Anne led various research groups at a number of pharmaceutical companies. She has a MSc in Pharmacy (Groningen University) and a PhD from the medical faculty of Utrecht University (the Netherlands). In 2003 she became the London Biotechnology Network’s "Young Entrepreneur of the Year” and since then has received numerous awards for her work with Px HealthCare.

Anne is a serial life-sciences entrepreneur. She recently founded Px HealthCare, the patient experience company optimising outcomes in oncology. As a data-analytics venture, Px aims to improve clinical outcomes in cancer using a validated personalized mobile medical support platform for cancer patients which collects and analyzes real-time, patient reported outcome data. Prior to founding Px HealthCare, she was the Executive Director of EPEMED, the European Personalized Medicine association. Before, Anne Bruinvels founded Curidium, a personalised medicine company focused on identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She started Curidium's business activities in 2001 and raised several rounds of angel funding before taking the company public on the AIM of the London Stock Exchange in 2006. Prior to founding Curidium, Anne was Scientific Director, Business Development at Pharmagene, where she contributed to the growth of the organization from private start-up to publicly listed biotechnology company. Before starting her entrepreneurial activities Anne led several neuroscience and genetics research groups at various pharmaceutical companies. She obtained her PhD from the Medical Faculty of Utrecht University (the Netherlands) and has a MSc degree in Pharmacy (Groningen, The Netherlands). Both Anne and her ventures have received a number of awards and prizes for leadership and innovation. Anne was appointed as a NHS Innovation Accelerator Fellow in 2015.


Darrin M Disley

Darrin M Disley

Dr Darrin M Disley

Darrin is a parallel entrepreneur, angel investor and enterprise champion. He has been involved in the start-up and growth of numerous business ventures securing over $300 million business financing from grant, angel, corporate, venture capital and public market sources as well as closing over $450 million of product, service, licensing and M&A deals.

He is currently the CEO and President of Horizon Discovery Group plc a company he led from a $275 thousand seed funding in March 2008 to a $113 million IPO exactly 6 years later. The funds raised by the IPO set a new record for a life science company on the AIM market and were the second largest by any research tools company in a London listing.

In 2012, he was named Business Leader of the Year at the European Life Science Awards, in 2014 was named biotech and pharma Executive of the Year by Scrip and in 2015 was named UK Quoted Company Entrepreneur of the Year, Cambridge Business Person of the Year and one of the 175 Faces of Chemistry by the Royal Society of Chemistry.

Darrin supports education, entrepreneurship and mentoring programs in the UK via the Professor Christopher R Lowe Carpe Diem Enterprise Fund and has backed over 30 start-up life science, technology and social enterprises. This led to him recently being conferred with an individual Queens Award for Enterprise Promotion in the 2016 birthday honours list.

He is an Entrepreneur in Residence at the Judge Business School and Enterprise Fellow at the Department of Chemical Engineering and Institute of Biotechnology both at the University of Cambridge. He is currently Chairman and co-founder of GeoSpock Ltd, Chairman of Desktop Genetics Ltd, Director and co-founder of Avvinity Therapeutics Ltd, Director of Cell Therapy Ltd, Board Member of the UK Bioindustry Association, Regional Council Member of the Confederation of British Industry and serves on the advisory boards of Axol Bioscience Ltd, GeneAdviser Ltd, HealX3 Ltd, Cambridge Ahead, the Cambridge Phenomenon, the Cambridge Science Centre and Biotech and Money as well as working with national and international bodies aimed at promoting the thriving UK life science industry.

https://www.linkedin.com/in/darrin-m-disley-7b1b8887


Patric Gresko

Patric Gresko

Patric Gresko joined EIF in 2001 and co-leads the Innovation and Technology Investment activity of EIF. EIF is the largest European venture capital fund-of-funds with more than €6bn under management and a portfolio of 300+ funds managed by a team of some 35 investment professionals. Patric started his career with PricewaterhouseCoopers in Luxembourg as an auditor and consultant for the financial sector. He holds a Master in Business Engineering from HEC Management School – Université de Liege.


Gwidon Idziak

Gwidon Idziak

For the last 20 years Gwidon has been successful in branding, product development and digital marketing. He combines all sectors of analysis, design and innovation building the business of his clients. He is a mentor of projects’ groups employing design thinking for projects’ development. Collaborating with Polish and international companies. A happy father of Helena, Marcelina and David. During his free time he is climbing on rocks or yachting.


Filip Jelen

Filip Jelen

Filip Jelen holds a PhD in Biochemistry from the University of Wroclaw and executive MBA from a Polish-American Business School. He is a founder and CEO of a leading Polish CRO/CMO company (Pure Biologics Ltd) providing services in the field of recombinant protein production and assay development and CEO at Captor Therapeutics focused on drug discovery. Captor Therapeutics is a pharmaceutical company focused on targeting the undruggable proteome silencing pathogenic proteins on posttranslational level and hence to transform patients' lives. Filip has over 15 years of Academic and 5 years of industrial experience working with biologics. At first as an adjunct at the Faculty of Biotechnology, University of Wroclaw, then as postdoctoral trainee with Noble Prize laureate, Ferid Murad at the Institute of Molecular Medicine, Univeristy of Texas and lately as a head of two biotechs. Co-author of numerous scientific papers, patents and marketed technologies.


Adam Jenkins

Adam Jenkins

Adam Jenkins is a senior Corporate Financier and Investor with more than 22 years of experience of mergers & acquisitions and debt and equity capital markets. He started his career in the City of London with Coopers&Lybrand in the special investigations unit an d subsequently moved to the lead advisory cross-border M&A division, advising private sector clients, go vernments, as well as multinational financial institutions such as EBRD, World Bank and Eu ropean Investment Bank. H e spent the next 15 years as a fund manager investing across a broad range of sectors i n listed and private companies in Europe, Middle East, Africa and Latin America fo r UBS Asset Management, Invesco Perpetual, Nomura Asset Management, and his own hedge fund Celeste. He came to Poland in 2012 to take up the position of Head of Equities and Balanced fu nds at Poland ’ s largest mutual fund Pioneer Pekao. In 2014 he joined Work Service S.A. and was appointed t he President of the Management Board of Work Service International, responsible for mergers and acquisiti ons, capital markets and investor relations for the entire Work Service Capital Group. In parallel to this appointment, in 2014, he founded ProPrimo a consultancy specializing in delivering innovative capital (debt and equity) raising solutions ; project management of IPOs, SPOs and cross- border dual-listings ; strategy and financial advisory services; lead M&A negotiation, structuring and valuation; and connecting international trading and commercial p artners. Ad am is the President of ProPrimo. His co -partners are senior consultants with extensive experience in capital markets, corporate finance, commercial law, strategic consulting and IR/PR.


Florence Korhonen

Florence Korhonen

Florence Korhonen NFBAN | Chairman of the Board

Florence is founder and Chair at NFBAN – Nordic Female Business Angel Network. She is also CEO at Miraflo Ventures Ltd, an investment company based in Finland, and believes that an Angel investor role is not simply one of financial investment but even more about providing knowledge, experience and networks to the benefit of the entrepreneur and the company. Florence is also a lead investor in the Rising Tide Europe 1 program, and a member of the Finnish Business Angel Network (FIBAN) as well as the European Impact Investment Committee (EIIC). She works with seed and early stage startups as an advisor and angel investor, and her main focus areas of investment are social impact investing, female investor networks and female entrepreneurship.

 

Katarzyna Koziak

Katarzyna Koziak

Dr. Katarzyna Koziak is a graduate cum laude from the Department of Embryology at the Faculty of Biology of University of Warsaw. Already as a student of Prof. Andrzej Tarkowski she joined the research team of Jacques Testart and Rene Frydman in Paris, France, where she worked on gametes maturation and clinical aspects of in vitro fertilization. After her return to Poland, dr. Koziak started to work at the Medical University of Warsaw where she in 1994 obtained her Ph.D. cum laude presenting a dissertation on erythropoietin production in kidney transplant recipients. Her scientific career continued in the United States, where she moved for a five-year postdoctoral training at Harvard Medical School. Working in Sandoz-founded Fritz Bach’s group dr. Koziak investigated endothelial cell biology and was one of the discoverers of NTPDase I, the key endothelial enzyme regulating vascular coagulation and homeostasis. Following her return to Poland, she continued research on vascular inflammation and in 2006 defended cum laude a habilitation (D.Sc.) dissertation. As an recognized and experienced researcher dr. Koziak participates as a principal investigator or co-investigator in several research projects in fields of vascular biology founded mostly by Polish Committee for Scientific Research, European Council, Polish National Science Center and Foundation of Polish Science. Dr. Katarzyna Koziak co-authored numerous research articles, text books and patent applications. She is also a recognized academic teacher, currently responsible for specialized curriculum in biochemistry for students of Medical University of Warsaw. Dr. Koziak’s achievements were recognized by Polish authorities – she received twice the award of Prime Minister of Poland.


Roland Kozlowski

Roland Kozlowski

Kozlowski received a first class honours degree from the University of Bath and a PhD from the University of Cambridge. He is a serial bioentrepreneur, investor and mentor who has worked in the industry for over twenty five years. Roland was Chief Executive Officer of Lectus Therapeutics and Sense Proteomic Limited two venture capital backed companies which he founded, built and sold. During his career Roland has lead or played a key role in a many transactions including com-pany financing, sale, purchase, financing and in- and out-licensing with a cumulative value of over $200m. Earlier in his career Roland ran Research Groups at the University of Oxford and University of Bristol where he published and patented in the life science field. He has been a Visiting Industrial Professor, served on, or advised the boards of several European companies and organizations including the Bio-Industry Association in the UK. Presently he is president and owner of Life Science Biznes Consulting which specializes in commercializing technology from emerging economies particularly in Poland. He acts as advisor to the National Centre of Research & Development in Poland and the Polish Development Agency. He is a founder and limited partner in Life Science Innovations a specialist VC fund based in Poland, an advisor to Alderley Park Ventures (UK) and a number of start-up companies who he also mentors.


Jakub Kur

Jakub Kur

Jakub Kur is CEO of PRF Ventures sp z o.o. which lies under the Polish Development Fund. At PFR Ventures he is focused on building a Fund of Funds in Poland with the mission to accelerate SME creation as well as the Venture Capital market in Poland.

 

Jakub's previous work experience was in the private sector at McKinsey & Company across Poland, Russia and the Netherlands focusing on strategy and operational excellence projects for market leading firms in the region. He also has experience in equities research acquired at Credit Suisse, finance and accounting at Boston Consulting Group, and the capital markets in a broker-dealer on Wall Street.

 

Jakub received his education at Northestern University in Boston where he studied Finance and Economics and has an international background having been brought up across Europe, Asia and North America.


Pawel Kurzynski

Pawel Kurzynski

Communications expert, specialist in R&D support instruments at the National Centre for Research and Development (NCBR) and previously at the Ministry of Science and Higher Education. Public Health graduate from the Warsaw Medical University with 8 years’ professional experience in government administration. Initiator and coordinator of the "Grants for success" campaign implemented in 2009-2011. Author of publications describing R&D support programmes and articles in the media and on the Internet. Since 2008 has delivered lectures on and trainings in EU Funds and national grant programmes.


Ron Landes

Ron Landes

Dr. Landes founded and currently serves as president of Solving Or gan Shortage, a nonprofit whose mission is to advance science-driven efforts to repair or fabricate replacement organs for transplantation by funding strategic, high-impact research initi atives. Previously he founded Landes Bioscience, publisher of 50 peer-reviewed bioscience journ als.

He serves on scientific advisory committees and Boards of seve ral early-stage bioscience companies and organizations, including Quantitative Insights, Biop , the Plant Neurobiology Society and the Georgian Telemedicine Association. Together wit h his family, Dr. Landes formed the Kelly-Landes Foundation to fund pilot programs tar geting women and children ’ s health issues in Kosovo and the Republic of Georgia.

Dr. Landes earned a BS in biochemistry from the University of Chicago, studied medicine at the Medical College of Wisconsin and trained in surgery at the Uni versity of Minnesota.


Melanie Lee

Melanie Lee

Dr Melanie Lee Ph.D. CBE, FMedSci. D.Sc (Hons). Chief Sci entific Officer for BTGplc Melanie ’ s academic grounding in molecular genetics involved three complex syst ems of DNA repair, recombination and cell cycle control. Melanie ’ s industrial career has been in research through Glaxo & GlaxoWellcome, leading R&D at Celltech/UCB , and as CEO of Syntaxin and NightstaRx . Melanie became CEO of venture backed Syntaxin in 2010 which was sold to Ip sen in 2013 and she was founding CEO for NightstaRx, a Syncona, Wellcome Trust company i n 2014. Melanie transitioned to the Board of NightstaRx at the end of 2014 to step down from the BTGplc Board and to take the role of Chief Scientific officer for BTGplc where she has been a member of the Leadership Team since January 2015. Within BTGplc the portfolio includes devices for loco-regional treatment of serious health conditions such as cancer, administered by specialist intervent ional physicians. Her non-executive positions have included Deputy Chairman Cancer Research U K, Chairman CRT, NED of BTGplc, Lundbeck A/S and NightstaRx Ltd. She is a Council Member for the Academy of Medical Sciences. Melanie has led R&D through many major mergers and integrations. She has lead R&D producing small molecule, biological drugs and de vices in a broad range of therapeutic areas.


Bogumila Matuszewska

Bogumila Matuszewska

CEO & CO-FOUNDER DROMNIBUS – a start-up, offering comprehensive multimedia solution that supports the therapy and development of children with special educational needs and children with behavioural and developmental disorders.

Bogumiła gained her experience as a marketing projects’ leader for global companies as well as a board member of the non-governmental organisation – Foundation Hippotherapy (which for over 25 years is engaged in children therapy). In DrOmnibus she is directly supervising products development and marketing. In 2014, DrOmnibus was awarded the Mobile Trends in the category “Education” and Bogumiła together with the other board members – Michał Ryś and Katarzyna Chrabąszcz – were on the list of the “Most creative in business”, according to the Brief magazine (2015). During the Central European Startup Awards contest she has been nominated as one of the Polish female representatives in the category “The most influential woman”.


Anna_Mitros

Anna Mitros

Anna Mitros performs as an Investment Supervising Director at Platinum Seed (www.platinumseed.pl), which focuses on providing seed capital to projects connected mainly with TMT, medicine, life sciences and renewable energy sources. The Platinum Seed portfolio contains 21 investments including co-?investments with Deutsche Telekom Venture Capital, Business Angels and large Polish corporations. Platinum Seed has been recognized by PARP (Polish Agency for Enterprise Development) as the Most Innovative Business Support Organization of 2015.

Anna is an expert in launching, development and commercialization of new startup ventures. As a member of Supervisory Boards is closely cooperating and mentoring startups from Platinum Seed portfolio.

Anna completed her studies in Business Economics at the Faculty of Management at the University of Gdańsk, and has completed post-graduate studies in Accounting and Finance and Taxes and Management.


Mark Preston

Mark Preston

Mark has been functioning in Poland since the very beginning of the country ’ s transformation, initially helping BP with its entry to Poland and then subsequent co ntracts with the Polish government in its Ministry of Privatisation followed by several years representin g Morgan Stanley in Poland. Since 2000, Mark has worked primarily with private equity funds in tackling especially difficult investment projects and situations – in the role of advisor or, frequently, as interim CEO or board member. In February 2016, Mark joined Biomed Lublin as Chief Restructuri ng Officer to lead the company through its application for restructuring under the new Polish restructuring law. Biomed Lublin became in June 2016 the first company in Poland to gain the necessary agreement from its creditors for restructuring under the new laws


Holger Reithinger

Holger Reithinger

Holger joined Forbion Capital Partners in 2010, heading the Munich o ffice. He holds a PhD in Biochemistry, which he obtained under the supervision of Prof. Dr. Arne Skerra (foun der of Forbion's portfolio company Pieris AG); all in the department of Prof. Dr. Hartmu t Michel (Nobel Laureate 1988) at the Max-Planck-Institute of Biophysics. As an undergraduate, Holger studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Hei delberg and Munich. After his studies, Holger gained operational experience as a product development manag er at Biometra/ Whatman Plc (now part of GE Healthcare). He started his career in Venture Capital in 1 997 as an Investment Manager at Technologieholding VC GmbH which at that time was one of the leading German Venture Capital firm. Technologieholding was acquired by the 3i Group in early 2000, where Holger became a Director at its Germany's healthcare practice. Following this assignment he became Principal and later Partner at Global Life Science Ventures, a well-established life sciences-focused partnership with offices in Switzerland and Germany. Holger has served on the Board s of numerous life sciences companies including Epigenomics (IPO 2004), MBT (assets sol d to Medigene AG), 4SC (IPO 2005), NeurogesX (IPO 2007), Fibrex Medical (assets licensed to Ikaria Inc.), Agendia BV and Santaris A/S (sold to Roche 2014). Holger holds board seats at Curetis NV (I PO 2015), Cellnovo Group S.A. (IPO 2015), Allecra Therapeutics GmbH and Rigontec GmbH.


Michal Rys

Michal Rys

CFO & CO-FOUNDER DROMNIBUS - a start-up, offering comprehensive multimedia solution that supports the therapy and development of children with special educational needs and children with behavioural and developmental disorders.

Michał gained his experience working for the venture capital fund but also as a board member of the non-governmental organisation - Foundation Hippotherapy (which for over 25 years is engaged in children therapy). He graduated in economics and finance from several European universities – Groningen, Uppsala, Leuven and Krakow, where in the last he is completing his Ph.D. Together with the other board members of DrOmnibus (awarded the Mobile Trends in the category “Education” 2014) he was on the list of the “Most creative in business”, according to the Brief magazine (2015). Laureate of the “Best business presentation” award during the jubilee edition of the “Life Science Open Space" of Klaster LifeScience in Krakow (2016).


Audra Shallal

Audra Shallal

Audra Shallal NFBAN | Board Member

Audra is an expert in Women Entrepreneurship and Angel Investment in the EMEA region. Audra promotes Entrepreneurship and Angel Investing through Programs, Mentoring, Business Plan Competitions, Business Angel Networks and Women Economic Empowerment within the EU and MENA region. She consults for international organizations such as OECD, UNEP, UNIDO and the European Commission. She is also co-leading the Mentoring Taskforce within the AmCham Women Leadership Committee and is an accredited Mentor for the Cherie Blair Foundation for Women and the BiD Network. She is a Member of the Board at NFBAN – Nordic Female Business Angel Network.


Marcin Szumowski

Marcin Szumowski

Marcin Szumowski is serial entrepreneur. He received his MS and PhD degrees from the University of Illinois and earned an MBA degree in entrepreneurship and international finance. Fo llowing a successful research career in the United States, Marcin has been involved in technology transfer and start-up companies since 2000 and has co-founded and managed five start-ups, in cluding a medical diagnostics company Medicalgorithmics S.A., where he was President and CEO 2005- 2010. Medicalgorithmics is now traded on the Warsaw Stock Exchange with a market cap of approx. $250 M and global sales. Since 2012 he is President & CEO of OncoArendi Therapeutics , a Polish innovative biopharmaceutical company dedicated to develop ing and commercializing novel therapeutics for neoplastic and inflammatory diseases . In three years the company has grown to over 50 employees and over $30M research funding from private investors and public grants. Marcin is also one of co-founders and lead investors in t he Life Science Innovations (LSI) early stage fund. Since 2012 Marcin has also assisted the European Commi ssion on independent expert panels performing the impact assessment and interim evaluations of the Inn ovative Medicines Initiative (IMI), the world ’ s largest public-private partnership (PPP) in pharmaceutical research. He also serv es on the Polish National Centre for Research and Development expert panel in Life Sci ences. Over the last 15 years Marcin has managed approx. 40 R&D and investment projects with a total val ue well over 200M euro.


Piyush Unalkat

Piyush Unalkat

Piyush joined the EIF in 2006 and is currently Head of Technology Transfer investments in the Innovation and Technology Investments team. Prior to EIF, Piyush held positions at the Genetrix Group (Madrid), Spark Ventures (Madrid), Dresdner Kleinwort (Madrid / London), and Barclays (London). He holds a PhD in Biochemistry from King’s College London, an M.Phil and a B.Sc. in Chemistry from the University of Cardiff and Karlsruhe Institute of Technology, together with an International MBA from IE Business School, Madrid.


Theresa Visarius

Theresa Visarius

Theresa Visarius holds a PhD in Pharmacology from Switzerland as well as degrees in biology and chemistry from the USA. In over 20 years of professional activity in the life sciences, she has assumed leading roles in research, academics and industry in the areas of cancer research, regenerative medicine, biomaterials, medical devices and pharma. Theresa has consulted for a number of global leaders in health care as well as start-ups, providing expertise and supplying evidence-based creative intelligence. She presently focusses on a breakthrough technology in the field of cancer immunotherapy with IPS Biopharma (Switzerland) / Immunophotonics (USA) and enjoys the challenges involved in bringing innovative medicine to the global market in both strategic and tactical roles. Additionally, Theresa is founder and owner of Visarius Consulting, is President of the Executive Board of the Competenzzentrum for Health Technology Assessment and resides with her husband and two children in Switzerland.


Ned Wakeman

Ned Wakeman

Director, BioHub at Alderley Park Director of the BioHub (managed by BioCity, the leading UK bioscience incubator). Ned is responsible for the strategic direction and leadership of the business, and establishing the Manchester Science Partnerships (formerly AstraZeneca) site at Alderle y Park as a leading centr e of excellence for early stage fast growing life science companies.

With proven sector expertise and awareness of market dynamics , Ned has been involved in excess of $250m of equity fund raisings for North American and European companies, which have current market valuations of over $2.0b.

Prior to investment banking, Ned conducted primary research i n neuropsychopharmacology, psychoneuroimmunology, and neuroscience at Yale Medical School and the University of Oxford.

Ned is on the advisory board of Alderley Park Ventures , a £5m fund which provides investment for early stages businesses on site.

BioCity specialises in the creation and development of life science businesses. It provides homes and access to high-end analytical equipment, shared services, training, business support, and access to investment for new and growing bioscience businesses. Over 250 compani es are based in a BioCity business incubator, making the BioCity network one of the largest concentrations of life science businesses in the UK. The 91% survival rate of companies at BioCity Nottingham tangibly demonstrates one of the benefits to a company being located with in the BioCity network. In 2012, BioCity established BioCity Scotland, near Glasgow, in 2013 the BioH ub at Aldeley Park, later MediCity on the Boots campus in Nottingham, and most recently Medi City in Scotland.


Nigel Whittle

Nigel Whittle

Nigel has over 25 years’ international experience in the life science industry, in a wide range of senior scientific, commercial and managerial roles. He obtained an honours degree in Biochemistry from the University of Oxford, then went on to complete a PhD in ground-breaking research at the Cancer Research UK Laboratories (London, UK). He has since worked for a number of premier biotechnology companies, including Genentech, Celltech and Cantab Pharmaceuticals.

He was recruited by the IPGroup private equity firm to drive the programme of technology commercialisation from Kings College London, including starting up Proximagen Neurosciences, which he helped float on AIM, raising £13 million. On leaving the company, Nigel joined UK Trade & Investment, working on two programmes to identify and broker high-value business deals, working with a portfolio of established overseas pharmaceutical companies to secure investment into the UK’s R&D capabilities worth over £100 million pounds.

He is currently working as an independent life science consultant, helping innovative biotechnology companies to achieve their scientific and commercial goals. His experience has encompassed companies in pharmaceutical development, precision medicine and genomic health, antibody technology, as well as eHealth and drug delivery technologies.

Nigel is on the scientific and advisory boards of a number of UK-based commercial and governmental organisations and governmental organisations (including the European Commission), and has been retained as a Key Opinion Leader by the Korean Biotechnology Organisation (KHIDI).


Miroslawa Zydron

Miroslawa Zydron

Mirosława Zydroń - Member of the Management Board, Director of Chemistry Department

Dr Miroslawa Zydron joined Selvita in December 2009, and has been responsible for the formation and organization of the Chemistry Services Division, strategic development of the chemistry research services, presentation of the company's offer and building relationships with international clients from the pharmaceutical, biotechnology, chemical and agrochemical environments, as well as overseeing the ongoing projects to ensure the highest quality of services. Dr. Zydron gained her experience in project management, formation of research and development structures and management of R&D teams in international organizations both in the scientific environment and Pliva company (then: Barr Pharmaceuticals, TEVA), as Head of R&D Laboratory, overseeing analytical and preformulation activities at the stage of drug form development and packaging processes in pilot production in GMP environment. Dr. Zydron graduated from the Silesian Technical University (Poland), with MSc and PhD Degree in chemistry. Her PhD Thesis gained distinction from Academy of Sciences, Committee of Analytical Chemistry, for the best doctoral thesis in the area of analytical chemistry in Poland in 2004 - 2005. In 2009, she completed a two-year MBA Program at the Rotterdam School of Management at Erasmus University in Rotterdam (Netherlands).